2 completed. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 2 |
Follow CAN04: new trials by email Literature Review of CAN04 trials Research Report on CAN04
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. Carboplatin, Gemcitabine, Nadunolimab - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 117 | 2022-01-11 | 2026-05-27 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors CAN04, Cisplatin, Gemcitabine - Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Cantargia AB | 167 | 2017-09-19 | 2024-08-22 |
Triple Negative Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Neoplasms (1)
Cantargia AB (2)
Spain (2) · Austria (1) · Belgium (1) · Denmark (1) · Estonia (1) · Germany (1) · Latvia (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Sweden (1)
2017 (1)